This study not only provides a novel metal-Cp*-based STAT3 inhibitor chemoimmunotherapeutic agents for treating colon cancer, but also further highlights the efficacy of the metal–ligand synergetic enhancement strategy in cancer treatment. This evidence concerns the gene STAT3 and malignant colon neoplasm.